eCommons@AKU
Department of Pathology and Laboratory
Medicine

Medical College, Pakistan

1-27-2021

Development of the Asia pacific consortium on osteoporosis
(APCO) framework: Clinical standards of care for the screening,
diagnosis, and management of osteoporosis in the Asia-pacific
region
M Chandran
Singapore General Hospital, Academia, Singapore

P J. Mitchell
Synthesis Medical NZ Limited, Auckland, New Zealand

T Amphansap
Police General Hospital, Bangkok, Thailand

S K. Bhadada
Postgraduate Institute of Medical Education and Research, Chandigarh, India

M Chadha
Hinduja Hospital and Research Centre, Mumbai, India

See next page for additional authors
Follow this and additional works at: https://ecommons.aku.edu/pakistan_fhs_mc_pathol_microbiol
Part of the Orthopedics Commons, and the Pathology Commons

Recommended Citation
Chandran, M., Mitchell, P. J., Amphansap, T., Bhadada, S. K., Chadha, M., Chan, D., Chung, Y., Ebeling, P.,
Gilchrist, N., Khan, A. H. (2021). Development of the Asia pacific consortium on osteoporosis (APCO)
framework: Clinical standards of care for the screening, diagnosis, and management of osteoporosis in
the Asia-pacific region. Osteoporosis International, 32(7), 1249-1275.
Available at: https://ecommons.aku.edu/pakistan_fhs_mc_pathol_microbiol/1309

Authors
M Chandran, P J. Mitchell, T Amphansap, S K. Bhadada, M Chadha, D-C Chan, Y-S Chung, P Ebeling, N
Gilchrist, and Aysha Habib Khan

This article is available at eCommons@AKU: https://ecommons.aku.edu/pakistan_fhs_mc_pathol_microbiol/1309

Osteoporosis International
https://doi.org/10.1007/s00198-020-05742-0

CONSENSUS STATEMENT

Development of the Asia Pacific Consortium on Osteoporosis (APCO)
Framework: clinical standards of care for the screening, diagnosis,
and management of osteoporosis in the Asia-Pacific region
M. Chandran 1 & P. J. Mitchell 2 & T. Amphansap 3 & S. K. Bhadada 4 & M. Chadha 5 & D.-C. Chan 6 & Y.-S. Chung 7 &
P. Ebeling 8 & N. Gilchrist 9 & A. Habib Khan 10 & P. Halbout 11 & F. L. Hew 12 & H.-P. T. Lan 13 & T. C. Lau 14 & J. K. Lee 15 &
S. Lekamwasam 16 & G. Lyubomirsky 17 & L. B. Mercado-Asis 18 & A. Mithal 19 & T. V. Nguyen 20 & D. Pandey 21 & I. R. Reid 22 &
A. Suzuki 23 & T. T. Chit 24 & K. L. Tiu 25 & T. Valleenukul 26 & C. K. Yung 27 & Y. L. Zhao 28 & on behalf of the Asia Pacific
Consortium on Osteoporosis (APCO)
Received: 2 October 2020 / Accepted: 11 November 2020
# The Author(s) 2021

Abstract
Summary Guidelines for doctors managing osteoporosis in the Asia-Pacific region vary widely. We compared 18 guidelines for
similarities and differences in five key areas. We then used a structured consensus process to develop clinical standards of care for
the diagnosis and management of osteoporosis and for improving the quality of care.
Purpose Minimum clinical standards for assessment and management of osteoporosis are needed in the Asia-Pacific (AP) region
to inform clinical practice guidelines (CPGs) and to improve osteoporosis care. We present the framework of these clinical
standards and describe its development.
Methods We conducted a structured comparative analysis of existing CPGs in the AP region using a “5IQ” model (identification,
investigation, information, intervention, integration, and quality). One-hundred data elements were extracted from each guideline. We then employed a four-round Delphi consensus process to structure the framework, identify key components of guidance,
and develop clinical care standards.
Results Eighteen guidelines were included. The 5IQ analysis demonstrated marked heterogeneity, notably in guidance on risk
factors, the use of biochemical markers, self-care information for patients, indications for osteoporosis treatment, use of fracture
risk assessment tools, and protocols for monitoring treatment. There was minimal guidance on long-term management plans or
on strategies and systems for clinical quality improvement. Twenty-nine APCO members participated in the Delphi process,
resulting in consensus on 16 clinical standards, with levels of attainment defined for those on identification and investigation of
fragility fractures, vertebral fracture assessment, and inclusion of quality metrics in guidelines.
Conclusion The 5IQ analysis confirmed previous anecdotal observations of marked heterogeneity of osteoporosis clinical
guidelines in the AP region. The Framework provides practical, clear, and feasible recommendations for osteoporosis care and
can be adapted for use in other such vastly diverse regions. Implementation of the standards is expected to significantly lessen the
global burden of osteoporosis.
Keywords Asia-Pacific . Consensus . Guidelines . Osteoporosis . Standards of care

Introduction
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Osteoporotic hip fractures among people in the Asia-Pacific
region are expected to increase dramatically due to population
aging, urbanization, and associated sedentary lifestyles [1]. Of
these factors, population aging represents the major challenge,
with the population of East Asia and the Pacific reported to be
aging more rapidly than any other region in history [2]. The
number of people who are 60 years and over in the Asia-
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Pacific region is predicted to triple between 2010 and 2050,
reaching an estimated 1.3 billion by 2050 [3]. The old-age
dependency ratio (OADR) is defined as the number of persons
aged 65 years or over (assumed to be economically inactive)
per 100 persons of working age (20 to 64 years). It provides an
index of the economic dependency associated with aging populations and is expected to more than double in Eastern and
South-Eastern Asia between 2019 and 2050, rising from 18
older persons per 100 workers in 2019 to 43 in 2050. It is
predicted that Japan which was reported to have the highest
OADR in the world in 2019 will remain in first position in
2050, followed closely by several other countries and regions
in Eastern and South-Eastern Asia [4].
The Asia Pacific Consortium on Osteoporosis (APCO), a
non-partisan and apolitical organization, is comprised of osteoporosis experts drawn from a diverse range of clinical settings, from low-, middle-, and high-income countries and regions in the Asia-Pacific that have populations ranging between 4.8 million and 1.4 billion people.
APCO aims to develop regionally relevant, pragmatic, and
effective strategies for improving osteoporosis management
and reducing rates of fragility fractures. Adoption of such strategies would lessen the burden of osteoporosis in this vast region
that accounts for more than 60% of the world’s population [5].
We have previously described APCO’s raison d’etre, conception and launch, vision, mission, and priority initiatives [6].
Launched in May 2019, APCO’s first project was to develop
clear and concise standards for the screening, diagnosis, and
management of osteoporosis that are pan Asia-Pacific in their
reach. This decision was based on anecdotal observations that
existing guidelines for osteoporosis management within the
Asia-Pacific region are heterogeneous and vary widely in scope
and recommendations. Access to primary care services and
bone mineral density (BMD) assessment varies across jurisdictions and regions, and little is known about adherence to current
guidelines in day-to-day clinical practice. APCO therefore determined to (i) conduct a systematic, structured analysis of
existing guidelines in the Asia-Pacific region, (ii) identify regionally relevant key guideline elements using a structured consensus process, and (iii) develop, through a structured consensus process, feasible regional clinical care standards that will
both support clinical improvement initiatives and provide a
framework for the development of new national clinical practice guidelines or the revision of existing ones.
This article describes the process by which, on a background of the existing guidelines in the Asia-Pacific region,
APCO members developed and endorsed a new set of minimum standards of care that can be adapted and adopted across
the region. We also highlight emerging themes in osteoporosis
that have not yet been incorporated into any of the existing
guidelines, but have enormous implications and potential to
change the landscape of osteoporosis treatment.

Methods
A framework of minimum clinical care standards (the
Framework) was developed in two stages: (i) a detailed comparative analysis of osteoporosis clinical practice guidelines in
the Asia-Pacific region, and (ii) a structured consensus process
to draft the standards.

Comparative analysis of osteoporosis guidelines in
the Asia-Pacific region
Existing national or regional clinical practice guidelines and/
or standards of care were identified through a survey among
APCO members. A structured template was developed to facilitate standardized identification of guideline components.
The template was based on the “5IQ” model (Table 1), modifications of which have been used to develop clinical standards for fracture liaison services (FLSs) in Japan [7], New
Zealand [8], and in the UK [9].
For each guideline, we identified the format in which the
recommendations/information were provided and extracted
details of these parameters. One hundred data elements
were extracted from each guideline (the template used for
extracting data from clinical practice guidelines is provided
in Appendix 1):
&
&
&
&
&

&
&

Background information (8 elements).
Case identification (34 elements). Checklists of risk factors were derived from a recent review examining casefinding strategies from a global perspective [10].
Investigation (21 elements).
Advice and education for patients (5 elements).
Interventions (28 elements), including indications for
treatment, treatments, recommendations for follow-up
and duration of treatment, and recommendations for
falls prevention. Given the complexity of indications, a coding system was created to allow quantitative comparison. Commentary on treatment/
supplementation with calcium and/or vitamin D was
also coded to compare the proportions of guidelines
that recommended these options as active therapy, as
distinct from adjunctive therapy alongside
osteoporosis-specific treatments.
Strategies for long-term management and integration of
osteoporosis care into the health system (2 elements).
Strategies to promote the quality of clinical care (2
elements).

Findings were analyzed separately for guidelines published
between 2015 and 2020 (“newer guidelines”) and those published before 2015 (“older guidelines”).
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Table 1 The 5IQ model for
analyzing the content of clinical
practice guidelines

Component

Description

Identification
Investigation
Information
Intervention
Integration

A statement of which individuals should be identified
A description of the types of investigations that will be undertaken
A description of the types of information that will be provided to the individual
A description of pharmacological interventions and falls prevention
A statement on the need for integration between primary and secondary care

Quality

A description of professional development, audit, and peer-review activities

Consensus process for developing the clinical care
standards framework
A four-round Delphi process was adopted to develop standards of care for osteoporosis risk assessment, diagnosis,
and management that are appropriate for the Asia Pacific region. The Delphi method has been widely used for establishing clinical consensus on other clinical conditions [11]. This
structured approach ensures that the opinions of participants
are equally considered, and it is particularly useful for geographically diverse groups like APCO. The Delphi process
was conducted through online questionnaires.

Round 1
APCO members were invited to determine which aspects of
care required clinical standards to be developed, based on a
list informed by the findings of the 5IQ comparative analysis.
The questionnaire included 32 questions under three domains
(Appendix 2):
&

&

&

Domain 1. What are the notable findings from the 5IQ
Comparative analysis of osteoporosis clinical guidelines
from across the Asia Pacific region? Participants were
referred to specific sections within the analysis report
and invited to identify important findings.
Domain 2: How should the Framework be structured?
Participants were asked to indicate how the Framework
should be structured, including whether levels of attainment should be included for clinical standards to serve as
potential quality performance indicators.
Domain 3. What clinical standards are required? For
each of 21 key elements identified in the 5IQ analysis
of Asia-Pacific clinical practice guidelines, participants were asked their opinion on the importance of
its inclusion as a clinical standard (5-point scale from
“extremely important” to “not at all important,” with
optional free text comments). Consensus was defined
as a ranking of “extremely important” or “very important” by at least 75% of respondents. Participants were
also invited to make any general comments on development of the Framework.

Round 2
Members were asked to express their agreement (or not) with the
wording of 16 draft clinical standards, of which several included
proposed wording on levels of attainment (5-point scale from
“strongly agree” to “strongly disagree”). For each draft standard,
members were also invited to propose alternative wording or
make comments. Consensus was defined as a ranking of “strongly agree” or “agree” by at least 75% of respondents.
Round 3
The wording of clinical standards and levels of attainment was
amended, based on the results of Round 2. APCO members
were invited to approve amendments (yes/no options).
Consensus was defined as a “yes” response to a proposed
rewording by at least 75% of respondents.
Round 4
A fourth round was conducted after some of the standards and
levels of attainment were again reworded for clarity and precision without changing their intent. The minor amendments
to the wording of the standards, with commentary itemizing
each change, were sent to the APCO members who had participated in one or more of the previous Delphi rounds.
Members were instructed to reply to the Chairperson by a
stipulated date if they had any objection to the rewording of
the standards.

Results
The analysis included 18 guidelines (Table 2) from the following regions: Australia [12], China (three guidelines)
[13–15], Chinese Taipei [16], Hong Kong Special
Administrative Region of the People’s Republic of China
(SAR) [17], India (two guidelines) [18, 19], Indonesia [20],
Japan [21], Malaysia [22], Myanmar [23], New Zealand [24],
the Philippines [25], Singapore [26], South Korea [27],
Thailand [28], and Vietnam [29]. Of these, 14 (78%) were
published between 2015 and 2020. Two-thirds of the
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Table 2

Osteoporosis management clinical practice guidance documents included in the 5IQ analysis

Country or
region

Organization(s)

Name of guideline

Australia

Osteoporosis Australia The Royal Australian College
of General Practitioners
China
Osteoporosis and Bone Mineral Disease Branch of Chinese
Medical Association
China
Osteoporosis Society of China Association of Gerontology and
Geriatrics
China
Osteoporosis Group, Orthopedic Branch, Chinese Medical
Association
Hong Kong SAR The Osteoporosis Society of Hong Kong
Chinese Taipei

Taiwanese Osteoporosis Association

India

Indian Menopause Society

India

Indian Society for Bone and Mineral Research

Indonesia

Indonesian Osteoporosis Association (Perhimpunan
Osteoporosis Indonesia)
Japan Osteoporosis Society The Japanese Society for Bone and
Mineral Research Japan Osteoporosis Foundation
Malaysian Osteoporosis Society Academy of Medicine
Ministry of Health Malaysia
Myanmar Society of Endocrinology and Metabolism
Osteoporosis New Zealand

Japan
Malaysia
Myanmar
New Zealand
Philippines

South Korea
Thailand

Osteoporosis Society of Philippines Foundation Philippine
Orthopedic Association
Agency for Care Effectiveness, Ministry of Health
Singapore
Korean Society for Bone and Mineral Research
Thai Osteoporosis Foundation

Vietnam

Vietnam Rheumatology Association

Singapore

guidelines did not specify a date for planned revision. Six
stated that an update within 3–5 years was planned.
Eleven of the guidelines were available in English. A professional medical translation agency was commissioned to
translate four guidelines from Chinese, and the Vietnamese
guideline was translated by an APCO member. Data extraction for the Japanese guidelines was undertaken by an APCO
member and that for the Korean guideline was undertaken by
a native speaker who was also an osteoporosis clinician.

Identification
Risk factors/indications for assessment and evaluation
Fifteen of the 18 guidelines cited risk factors separately for
men and women, two guidelines for women only, and another
did not state the sex to which cited risk factors applied.

Osteoporosis prevention, diagnosis and management in
postmenopausal women and men over 50 years of age [1]
Guidelines for the diagnosis and treatment of primary
osteoporosis [2]
2018 China guideline for the diagnosis and treatment of senile
osteoporosis [3]
Guidelines for the diagnosis and treatment of osteoporotic
fractures [4]
OSHK guideline for clinical management of postmenopausal
osteoporosis in Hong Kong [5]
Consensus and guidelines for the prevention and treatment of
adult osteoporosis in Taiwan [6]
Clinical practice guidelines on postmenopausal osteoporosis:
An executive summary and recommendations [7]
Indian Society for Bone and Mineral Research guidelines
2020 [8]
Summary of the Indonesian guidelines for diagnosis and
management of osteoporosis [9]
Japanese 2015 guidelines for the prevention and treatment of
osteoporosis [10]
Clinical guidance on management of osteoporosis [11]
Myanmar clinical practice guidelines for osteoporosis [12]
Guidance on the diagnosis and management of osteoporosis in
New Zealand [13]
Consensus statements on osteoporosis diagnosis, prevention,
and management in the Philippines [14]
Appropriate care guide: osteoporosis identification and
management in primary care [15]
KSBMR Physician's Guide for Osteoporosis [16]
Thai Osteoporosis Foundation (TOPF) position statements on
management of osteoporosis [17]
Guidelines for the diagnosis and treatment of osteoporosis [18]

The most commonly cited risk factors for osteoporosis (cited in at least half the guidelines) were excessive alcohol consumption (17 guidelines), a family history of osteoporosis
and/or fractures (17 guidelines), smoking (17 guidelines),
low body mass index (BMI)/weight (16 guidelines), height
loss (13 guidelines), age over 70 years (13 guidelines), and
early menopause (12 guidelines).
A range of other age thresholds for increased risk was also
identified, with several citing one or more of the following:
adults (four guidelines), postmenopausal women (three guidelines), 50 years and above (two guidelines), 60 years and above
(one guideline), and 65 years and above in men (one guideline).
All 18 guidelines cited a history of fragility fracture as a
risk factor for subsequent fracture. Thirteen of 18 guidelines
specified the type of fragility fractures, most commonly spine,
hip, proximal femur, wrist, forearm, distal radius, humerus,
pelvis, and ribs. In the context of case identification, one
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guideline from China mentioned the importance of FLSs to
promote multidisciplinary joint diagnosis and treatment.
While all the guidelines identified glucocorticoid treatment
as being associated with bone loss and/or increased fracture
risk, the lists of other medicines associated with bone loss
varied between guidelines. More than half of the guidelines
also identified users of androgen deprivation therapy (11/18
guidelines), anticoagulants (9/18 guidelines), anticonvulsants
(10/18 guidelines), and aromatase inhibitors (11/18 guidelines) as at-risk groups. Other medications that were identified
included proton pump inhibitors, thiazolidinediones, and selective serotonin reuptake inhibitors.
The medical conditions most frequently cited as risk factors
were rheumatoid arthritis, malabsorption, hyperthyroidism,
and multiple myeloma. Diabetes was noted as a risk factor
in 10 of 14 (71%) of the newer guidelines, compared with
none of the older guidelines.

Investigation
Biochemical tests
The extent of commentary on assays for bone turnover
markers and other biochemical parameters varied considerably between the guidelines. Some guidelines only briefly
mentioned biochemical tests in the evaluation of osteoporosis,
while others provided detailed guidance. Total procollagen
type 1 N-terminal propeptide (P1NP) was the most frequently
recommended bone turnover marker (16/18 guidelines). Other
laboratory tests that were commonly recommended in the
guidelines included calcium, alkaline phosphatase, 25hydroxyvitamin D, creatinine, urinary N-telopeptide
(uNTX), parathyroid hormone (PTH), and osteocalcin.
Risk assessment tools
The FRAX® fracture risk assessment tool [30] was by far the
most commonly recommended risk assessment tool (17/18
guidelines), followed by the Osteoporosis Self-Assessment
Tool for Asians (OSTA) (11/18 guidelines) [31]. Some newer
guidelines also recommended a range of other tools: the
Garvan nomogram [32] (three guidelines), IOF Risk Check
(“one-minute osteoporosis risk test”)[33] (three guidelines),
the Khon Kaen Osteoporosis Study (KKOS) scoring system
[34] (one guideline), the Male Osteoporosis Risk Estimation
Score (MORES) [35] (1 guideline), QFracture algorithm [36,
37] (one guideline), and Simple Calculated Osteoporosis Risk
Estimation (SCORE) [38] (one guideline).

the thoracic and lumbar spine, some advising when it should
be considered, and one simply noting that bone loss and
healing fractures may be evident on radiographs. Dualenergy x-ray absorptiometry (DXA)–based vertebral fracture
assessment (VFA) was mentioned in eight guidelines, with
guidance ranging from just statements of its existence or simple advice to consider DXA for identifying fractures, to the
inclusion of DXA-identified fractures in treatment indications.
Falls risk assessment
Thirteen of 18 guidelines referred to the importance of
falls risk assessment. The degree of detail varied widely
with some amount of detail specified in the guidelines
from Australia, China, Hong Kong SAR, Chinese
Taipei, India, Malaysia, Japan, Thailand, and New
Zealand. Some guidelines emphasized that falls risk assessment should be conducted routinely in all older adults
(Australia), while others discussed falls risk assessment
for patients known to be at risk of fragility fractures or
with a history of fracture. One of the Chinese guidelines
recommended that attention should be paid to the evaluation of fall-related risk factors in elderly patients with
osteoporosis. Some guidelines recommended certain aspects of assessment, such as muscle strength and balance,
while the Hong Kong SAR and one of the other Chinese
guidelines provided comprehensive guidance on specific
medical and environmental risk factors to consider when
performing the assessment. Some mentioned strategies or
structured tools for performing falls risk assessment
(Thailand).
Specialist assessment
Ten of 18 guidelines recommended specialist referral for assessment in certain clinical scenarios. Four recommended that
any patient with fragility fractures or osteoporosis should be
referred for specialist assessment or care. Other specified scenarios included fracture or persistent loss of BMD despite
treatment, complex conditions, problems considered “difficult” or beyond the scope of primary care, secondary osteoporosis, severe or unusual presentation, when first-line treatments were contraindicated or not tolerated, when assessment
for specialized treatments is needed (e.g., teriparatide or longterm estrogen therapy), and when bone densitometry is not
available.

Information
Vertebral fracture assessment
All 18 guidelines mentioned the use of radiography to identify
vertebral fractures, with some directly recommending x-ray of

There was considerable variation in the extent to which the
various guidelines recommended that specific information
should be provided to patients.
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Calcium intake and exercise
All 18 guidelines recommended that information should be
provided on calcium intake, and 17 recommended providing
information on exercise.
Sun exposure
Ten out of 18 guidelines (including one older guideline) recommended that patients should be provided with information
on sun exposure to maintain healthy vitamin D levels.

the guidelines from China [15] stated that the current prediction results may underestimate fracture risk in the Chinese
population. Several others recommended the use of population specific FRAX® algorithms (e.g., Hong Kong SAR,
India, Singapore, Thailand, Vietnam).
Osteopenia in combination with other criteria (e.g., presence of risk factors, risk scores, ≥ 10 years post menopause)
was included in several guidelines.
Pharmacological treatment options

Intervention

Less than one-third of guidelines classified treatment options
as first line, second line, and third line. All guidelines recommended bisphosphonates (oral and intravenous) and raloxifene as treatment options for osteoporosis. Most guidelines
also recommended denosumab, teriparatide, and hormone replacement therapy (HRT). Predictably, the recently introduced treatments, abaloparatide and romosozumab, were recommended in only two newer guidelines (India and Korea).

Indications for treatment

Adjunctive treatments

All 18 guidelines cited BMD T-score of ≤ − 2.5 standard
deviations (SD) as an indication for treatment. The reference
database to be used to delineate T-scores was specified in only
a minority of the guidelines. A broad range of other indications for treatment were cited in the various guidelines, with
each guideline typically featuring three or four of a total of 14
indications identified.
Most guidelines cited hip and vertebral fractures as an indication for treatment. Fifteen of the 17 guidelines that included hip fracture as an indication for treatment, and all 17 guidelines that included vertebral fracture as an indication for treatment, stated that BMD testing was not required to initiate
treatment. Of the 15 guidelines that included non-hip, nonvertebral fracture as an indication for treatment initiation, nine
suggested that BMD testing was not necessary prior.
Thirteen guidelines mentioned or recommended treatment
thresholds based on FRAX® probabilities. Six guidelines cited
the threshold recommended by the US National Osteoporosis
Foundation guidelines [39] (BMD T-Score in the osteopenic
range, in combination with a FRAX® 10-year probability of
≥ 3% for hip fracture risk or ≥ 20% for major osteoporotic
fracture risk). Of these, only two (the Malaysian guideline and
one of the guidelines from China) explicitly recommended that
this threshold should be adopted for their local target population. The Hong Kong SAR guideline stated that the US criteria
were provided for clinical guidance only and that treatment
decisions should consider individual patient factors. Other
guidelines cited the US treatment threshold as an example or
in commentary, without further interpretation.
Some guidelines provided guidance on the logistics and
limitations of applying FRAX® to local populations. One of

Calcium and vitamin D were recommended as adjunctive
therapies more often than as active treatments. That calcium
was not a treatment option was explicitly stated in less than
half of the guidelines.

Fracture risk
Only seven out of 18 guidelines (all newer guidelines) recommended that patients should be given information about the
link between osteoporosis and fracture risk.

Adverse effects
The volume of commentary on potential adverse effects of
osteoporosis treatments varied considerably between guidelines. Eleven of 18 guidelines provided information on adverse effects associated with all or several classes of antiosteoporosis agents.
Monitoring therapeutic response and long-term follow-up
Almost all the guidelines provided information on the
role of repeated measurements of BMD and biochemical
markers of bone turnover in monitoring. Some specified
intervals for repeating tests (Table 3). Overall, there was
limited guidance on making long-term management
plans and providing them to the patient or primary care
provider. Only two guidelines explicitly stated the need
for a long-term plan, while 8 others implied the need
for such planning.
Treatment duration
Duration of treatment was specified in 13 guidelines and
discussed very generally in two others. Most guidelines
advised using bisphosphonates for 3–5 years before
reassessing to determine whether to continue or
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Table 3

Recommendations for timing of bone densitometry in follow-up

Guideline

Mode

First test (if stated separately)

Intervals for repeat tests (if stated)

Australia

DXA

–

≥ 2 years when considering efficacy of
treatment, risk assessment or decision
to change or interrupt treatment
Every 1 year in patients at high risk
–

China
DXA
1 year after starting treatment
(Orthopedic)
China (CSOBMR) Unspecified (bone density measurement) 1 year after starting or changing treatment Every 1–2 years when effect has stabilized
China (Geriatrics) DXA or QCT (if available)
–
Unspecified
(Monitor efficacy)
Biochemical markers of bone turnover –
Every 3–6 months
Chinese Taipei
DXA
2 years after starting treatment
–
< 2 years after starting treatment in
patients with glucocorticoid-induced
osteoporosis
Hong Kong SAR BMD (not specified)
1–2 years after starting treatment in
2–3 after therapeutic effect established
patients treated with antiresorptive
treatment
1 year after starting
treatment in patients treated with
bone-forming agents
India (IMS)
DXA (use same DXA machine)
–
2 years
India (ISBMR)

DXA (if available)

–

2 years

Indonesia

BMD (not specified)

–

Japan

BMD (not specified)

1 year after starting treatment

1–2 to evaluate treatment response (defined
as stable over 1 year)
> 1 year (unspecified)—after 1 year’s
treatment with bisphosphonates, intervals
longer than 1 year needed to see change
in BMD

Malaysia

DXA

Not specified

New Zealand

BMD (not specified)

Singapore

DXA

South Korea

DXA

4–5 years after starting treatment to
determine whether bisphosphonates
treatment should continue
1–2 years after starting treatment to
establish clinical effectiveness
–

Thailand
Vietnam

DXA (Use same axial DXA analyzer)
Not specified

–
1–2 years

Not specified
(Monitoring the effect of therapy)
≥ 3 years (intervals < 3 years not
recommended in most patients)
Every 2–3 years after clinical effectiveness
established
Every 1 year until normal BMD
(T-score > − 1.0)2 years after previous
normal BMD
> 1 year
1–2 years

BMD bone mineral density, DXA dual-energy X-ray absorptiometry, QCT quantitative computed tomography

discontinue with observation (“drug holiday”), based on
assessment of treatment response and fracture risk.
Another guideline recommended continuing bisphosphonate therapy for 5–10 years before reconsideration.
Several guidelines gave detailed guidance based on risk
assessment. Three guidelines recommended that
teriparatide treatment should not exceed 2 years, while
one guideline recommended 3 years of treatment with
teriparatide. Of the four guidelines that discussed HRT
and mentioned initiation of, and duration of therapy
with it, one (Australia) recommended that its long-term

use is not recommended. The Hong Kong SAR guideline recommended that patients should be adequately
counselled on the risks and benefits of long-term use
(beyond 3-5 years for combined estrogen-progesterone
therapy and beyond 7 years for Estrogen alone therapy).
The Indian Menopause Society guideline recommended
it as first line therapy for women with menopausal
symptoms for up to 10 years after menopause and specifically stated that HRT should not be started solely for
bone protection after 10 years of menopause. The guidance from Singapore specified that menopausal hormone
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therapy can be considered for prevention of osteoporosis
and fragility fractures in women who experience early
menopause and that it can be continued until the normal
age of menopause unless contraindicated. Of the two
guidelines that mentioned duration of denosumab therapy, one recommended long-term use and the other recommended reevaluation of fracture risk after 5–10 years.

Adherence
Nine guidelines made specific recommendations on assessing
and encouraging adherence.

Conclusions of the comparative analysis of existing
guidelines
The 5IQ analysis confirmed previous anecdotal findings
of marked heterogeneity among clinical practice guidelines for osteoporosis in the Asia-Pacific region—
notably in guidance on risk factors, the use of biochemical
bone turnover markers, self-care information for patients,
indications for osteoporosis treatment, the use of fracture
risk assessment tools, and protocols for monitoring treatment. Minimal guidance was provided on long-term management plans. Few mentioned strategies and systems for
ensuring clinical quality improvement.

Outcomes of the Delphi process
Falls prevention programs
Five guidelines made specific recommendations for referral to
falls prevention programs. A further three guidelines provided
detailed commentary on falls risk assessment.

Integration
Overall, there was limited commentary on the need to develop
a long-term management plan and provide it to the primary
care provider and/or the patient. Only two guidelines explicitly referred to the need for a long-term care plan, while eight
others implied that this was needed.
Though not specifically referring to the concept of integration and long-term planning, one guideline (South Korea) recommended the development of a secondary fracture prevention program that would be practical and suitable for their
country to reduce re-fracture rates.

The surveys were sent to current APCO members (n = 39), of
whom 29 participated in one or more of the four rounds.
Respondents were drawn from 18 countries/regions viz
Australia (3), Brunei (1), China (1), Hong Kong SAR (2),
Chinese Taipei (1), India (3), Japan (1), Korea (1), Malaysia
(2), Myanmar (1), Nepal (1), New Zealand (3), Pakistan (1),
Philippines (1), Singapore (2), Sri Lanka (1), Thailand (2), and
Vietnam (1) and from the International Osteoporosis
Foundation (1).
Round 1
Consensus was reached on the inclusion of clinical standards
on the following components (i.e., ≥ 75% rated its inclusion as
important or extremely important (Table 4)):
&
&

Quality
In general, there was limited commentary on audit of
practice against standards, or on continuing professional
development and learning that is required. One guideline
(Chinese Taipei) advocated benchmarking the performance of FLSs against the IOF Capture the Fracture®
best-practice framework standards [40]. Another (New
Zealand) recommended auditing against national clinical
standards for FLSs. One guideline (Malaysia) included an
audit question to assess post-hip fracture osteoporosis
care. The need for a national hip fracture registry was
noted in one guideline (India). Several guidelines identified dissemination of clinical practice guidelines and ongoing continuing professional development as priorities
for healthcare professionals involved in the provision of
care for people living with osteoporosis.

&
&
&
&
&
&
&
&
&

Identification of individuals with fragility fractures
Identification of individuals with common risk factors for
osteoporosis, such as age 70 years or above, early menopause, excessive alcohol intake, family history, height
loss, low body mass index/weight, prolonged immobility,
smoking
Identification of individuals who take medicines associated with bone loss and/or increased fracture risk
Identification of individuals with conditions associated
with bone loss and/or increased fracture risk
Use of risk assessment tools
Vertebral fracture assessment
Falls risk assessment
Information provided to patients on self-care, such as calcium intake, sun exposure, the relationship between osteoporosis and fracture risk, exercise
Indications for treatment to include hip fracture, vertebral
fracture, and non-hip non-vertebral facture
Recommendations for pharmacological interventions for
specific patient subgroups
Recommendations for nonpharmacological interventions
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Table 4

Delphi round 1 responses

Component

Inclusion of standard on this component
Extremely
important

Very
important

Somewhat
important

Not so
important

Not at all
important

Consensus (% rating as
extremely or very
important,
i.e., ≥ 75%)

22
12
7

3
10
15

0
2
3

0
0
0

0
0
0

Yes (100%)
Yes (92%)
Yes (88%)

5

16

4

0

0

Yes (84%)

5
8
12
14
9
4
14

11
9
9
5
13
11
7

8
8
3
4
3
8
4

1
0
1
1
0
2
0

0
0
0
0
0
0
0

No
No
Yes (84%)
Yes (79%)
Yes (88%)
No
Yes (84%)

10
4
6
11
13
8
5

12
16
15
11
8
12
13

3
4
3
3
4
3
6

0
1
1
0
0
2
0

0
0
0
0
0
0
0

N/A
Yes (88%)
Yes (80%)
Yes (84%)
Yes (88%)
Yes (84%)
Yes (80%)
No

11

9

4

1

0

Yes (80%)

10

12

2

1

0

Yes (88%)

Identification
Fragility fracture
Risk factors for osteoporosis
Medicines associated with bone
loss/fracture risk
Medical conditions associated
with bone loss/fracture risk
Investigation
Biochemistry
BMD testing
Risk assessment tools
Vertebral fracture assessment
Falls risk assessment
Specialist referral
Information for patients
Intervention
Indications—see Table 5
Pharmacological
Non-pharmacological
Side effects
Monitoring effect
Duration
Adherence
Falls programs
Integration
Long-term management plans
Quality
Adherence to guideline-based
care

Respondents’ priority ratings for each of the key components identified in existing clinical practice guidelines. Consensus was defined as a rating of
extremely important or very important by at least 75% of respondents

&
&
&
&
&
&

Description of side effects of pharmacological treatments
Monitoring of pharmacological treatment
Duration of pharmacological treatment
Adherence to pharmacological treatment
Provision of long-term management plans to patients and/
or primary care providers
Quality metrics for adherence to guideline-based care.

Sixteen standards were drafted based on this consensus. Although the initial intention was to draft levels of
attainment for each standard, only a few standards proved
amenable to this approach after collating respondents’
comments on priority rankings and levels of attainment.
Levels of attainment were therefore drafted initially for

five standards viz for those on (a) identification of fragility fractures, (b) identification of patients with common
risk factors, (c) investigation of vertebral fractures, (d)
assessment of adherence to pharmacological treatment,
and (e) quality metrics to assess clinical adherence to
guidelines. Each of these five standards had three levels
of attainment, stratified according to degree of difficulty
or feasibility of implementation.
Round 2
Consensus was reached (i.e., ≥ 75% of respondents strongly
agreed or agreed) on the wording of all 16 standards (Fig. 1).
Agreement was unanimous or nearly so (> 90% agreement)
for the wording of draft standards on:
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Fig. 1 Delphi second-round
consensus on wording of
standards. The proportion of
respondents who voted “strongly
agree” or “agree” on the wording
of 16 draft clinical practice
standards

&
&
&

Proactive case identification based on medicines associated with bone loss/increased fracture risk
The use of country-specific fracture risk assessment tools,
vertebral fracture assessment, and falls risk assessment
Duration of pharmacological treatment and adherence to
pharmacological treatment

Table 5 Delphi round 1
responses: indications for
initiating osteoporosis-specific
treatment

&
&

Long-term management plans
Metrics for adherence to guidelines

Diversity of opinion was greatest for the wording of the
draft standard on proactive case identification based on

Indications

Selected (n)
Yes

No

Consensus (% rating as
extremely or very
important, i.e., ≥ 75%)

Hip fracture
Vertebral fracture
Non-hip non-vertebral fracture
BMD T-score ≤ − 2.5 SD
Osteopenia + FRAX® ≥ 3% hip or ≥ 20% MOF
Osteopenia + RFs or eligible by OSTA or SCORE

24
24
20
18
11
7

1
1
5
7
14
18

Yes (96%)
Yes (96%)
Yes (80%)
No
No
No

Osteopenia + ≥ 10 years post menopause
FRAX® or Garvan ≥ 3% hip or ≥ 20% MOF
Eligible by OSTA, MORES, or SCORE
QCT
Height loss > 4 cm
Androgen deprivation therapy
Aromatase inhibitor treatment
Glucocorticoid treatment
Country-specific thresholds

3
9
1
2
11
10
9
17
14

23
16
24
23
14
6
16
8
11

No
No
No
No
No
No
No
No
No

BMD bone mineral density, MORES Male Osteoporosis Risk Estimation Score, OSTA Self-Assessment Tool for
Asians, SCORE Simple Calculated Osteoporosis Risk Estimation, QCT quantitative computed tomography
The percentage of APCO member respondents who rated each of the proposed indications for initiating osteoporosis treatment identified in existing clinical practice guidelines, as extremely or very important for inclusion in
APCO clinical practice standard 9
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common risk factors, although consensus was reached. The
volume of comments (excluding minor editing suggestions)
was highest for the standards on, medicines associated with
risk, assessment of vertebral fractures, intervention thresholds
for osteoporosis-specific therapies (Table 5), and assessment
of adherence to pharmacological therapies.
Draft standards from which levels of attainment were subsequently removed Of the five standards that had levels of attainment drafted, consensus was reached on the wording of all
except those on identification of patients with common risk
factors (69.6% voted “strongly agree” or “agree”). For this
standard, the proposed levels were as follows: Level 1—
identification of individuals with common risk factors to include alcohol intake of ≥ 2 units per day, a family history of
osteoporosis or fragility fracture, BMI ≤ 20 kg/m2, or a history
of smoking. Level 2—identification of individuals with Level
1 common risk factors plus age ≥ 70 years and/or height loss
of ≥ 4 cm compared to maximum height as a young adult.
Level 3—identification of individuals with Level 1 and 2
common risk factors plus early menopause (defined as occurring before 45 years) and/or prolonged immobility. Issues noted by respondents for this included the difficulty of
implementing these levels of attainment and the omission of
particular risk factors (prolonged glucocorticoid use and falls
risk). There were also concerns about defining levels according to numbers of risk factors, with suggestions that the levels
should instead represent increasing percentages of at-risk patients identified, or be defined by the approach to case-finding,
e.g., whether at-risk individuals are identified systematically
or otherwise. Given the significant discordance among the
participants, it was therefore decided by consensus that this
standard would not be amenable to levels of attainment.
The threshold for consensus (75%) was reached on the
wording of draft attainment levels for the standard on assessment of adherence to pharmacological therapy, but levels were
not retained after several respondents queried the selection of
cut-points and the feasibility of implementing the levels.
Thus, out of the five standards that were originally drafted
with levels of attainment, we retained the levels in only three
of them. These three standards were on (a) identification of
fragility fractures, (b) investigation of vertebral fractures, and
(c) quality metrics to assess clinical adherence to guidelines.
Members proposed alternative wordings for several standards and levels of attainment, including several of those that
reached consensus. The chairperson and project manager analyzed the suggestions and drafted amendments.

standards. At the end of this round, consensus had been
reached on the final Framework of minimum clinical
standards.
Round 4
There were no objections to the minor amendments proposed to
improve clarity and precision of the wording of some of the
standards.

APCO Framework
Clinical standard 1 Men and women who sustain a fragility
fracture should be systematically and proactively identified to
undergo assessment of bone health and, where appropriate, falls
risk.
Levels of attainment for clinical standard 1:
&
&
&

Level 1: Individuals who sustain hip fractures should be
identified.
Level 2: Individuals who sustain hip and/or clinical vertebral fractures should be identified.
Level 3: Individuals who sustain hip, clinical and/or morphometric vertebral, and/or non-hip, non-vertebral major
osteoporotic fractures should be identified.

Clinical standard 2 Men and women with common risk factors
for osteoporosis should be proactively identified to undergo
assessment of bone health and, where appropriate, falls risk. A
sex-specific age threshold for assessment should be determined for each country or region and should be included in
new or revised osteoporosis clinical guidelines.
Clinical standard 3 Men and women who take medicines that
are associated with bone loss and/or increased fracture risk
should be proactively identified to undergo assessment of
bone health and, where appropriate, falls risk. A commentary
should be included in new or revised osteoporosis clinical
guidelines to highlight commonly used medicines that are
associated with bone loss and/or increased fracture risk.
Clinical standard 4 Men and women who have conditions
associated with bone loss and/or increased fracture risk should
be proactively identified to undergo assessment of bone
health. A commentary should be included in new or revised
osteoporosis clinical guidelines to highlight common prevalent conditions in the country or region.

Round 3
Consensus was achieved on all the proposed amendments,
involving six standards, and levels of attainment for two

Clinical standard 5 The use of country-specific (if available)
fracture risk assessment tools (e.g., FRAX®, Garvan, etc.) or
osteoporosis screening tools (e.g., OSTA) should be a
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standard component of investigation of an individual’s bone
health and prediction of future fracture risk and/or osteoporosis risk.
Clinical standard 6 Assessment for presence of vertebral
fracture(s) either by X-ray (or other radiological investigations such as CT or MRI), or by DXA-based VFA
should be a standard component of investigation of osteoporosis and prediction of future fracture risk.
Levels of attainment for clinical standard 6:
&
&
&

Level 1: Individuals presenting with clinical vertebral fractures should undergo assessment for
osteoporosis.
Level 2: Individuals with incidentally detected vertebral
fractures on X-ray and/or other radiological investigations
should be assessed for osteoporosis.
Level 3: Individuals being assessed for osteoporosis
should undergo spinal imaging with X-ray or other appropriate radiological modalities, or with DXA-based VFA.

Clinical standard 7 A falls risk assessment should be a standard component of investigation of an individual’s future fracture risk.
Clinical standard 8 In order to engage individuals in their own
care, information should be provided on calcium and vitamin
D intake, sun exposure, exercise, and the relationship between
osteoporosis and fracture risk.
Clinical standard 9 The decision to treat with osteoporosisspecific therapies and the choice of therapy should be informed as much as possible by country-specific and costeffective intervention thresholds. Intervention thresholds that
can be considered include:
&
&
&

History of fragility fracture
BMD T-score ≤ − 2.5 S.D.
High fracture risk as assessed by country-specific intervention thresholds

Clinical standard 10 New or revised osteoporosis clinical
guidelines should include a commentary on the common side
effects of pharmacological treatments that are recommended
in the guidelines.
Clinical standard 11 New or revised osteoporosis clinical
guidelines should provide a commentary on monitoring of
pharmacological treatments. This could include, e.g., the role
of biochemical markers of bone turnover and bone mineral
density measurement.

Clinical standard 12 New or revised osteoporosis clinical
guidelines should provide a commentary on the duration of
pharmacological treatments that are recommended in the
guidelines. This should include a discussion on the appropriate order of sequential treatment with available therapies and
the role of “drug holidays.”
Clinical standard 13 Assessment of adherence to pharmacological treatments that are recommended in new or revised osteoporosis clinical guidelines should be undertaken on an ongoing
basis after initiation of therapy, and appropriate corrective action be taken if treated individuals have become non-adherent.
Clinical standard 14 New and revised osteoporosis clinical
guidelines should provide a commentary on recommended
non-pharmacological interventions, such as exercise and nutrition (including dietary calcium intake) and other nonpharmacological interventions (e.g., hip protectors).
Clinical standard 15 In collaboration with the patient, the
treating clinician (hospital specialist and/or primary care provider) should develop a long-term management plan that provides recommendations on pharmacological and nonpharmacological interventions to improve bone health and,
where appropriate, measures to reduce falls risk.
Clinical standard 16 New or revised osteoporosis clinical
guidelines should provide a commentary on what quality metrics should be in place to assess adherence with guidelinebased care.
Levels of attainment for clinical standard 16:
&
&
&

Level 1: Conduct a local “pathfinder audit” in a hospital or
primary care practice to assess adherence to APCO
Framework clinical standards 1–9, 13, and 15.
Level 2: Contribute to a local fracture/osteoporosis
registry.
Level 3: Contribute to a fracture/osteoporosis registry for
your country or region.
The clinical standards are shown in Appendix 3.

Discussion
The 5IQ analysis of the multiple clinical practice guidelines on
osteoporosis from Asia-Pacific countries and regions confirmed our understanding, based on previous anecdotal reports, that existing guidelines were markedly heterogeneous
in terms of their scope and recommendations. The findings
enabled APCO members to prioritize and select elements
through the Delphi consensus method. The resulting
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minimum standards for care for the Asia-Pacific region are
relevant, pragmatic, and feasible to implement.

Application of the Framework to clinical practice
guidelines
Clinicians need information that is clear and readily accessible. Osteoporosis guidelines should clearly articulate which
individuals should be identified for assessment, the investigations that should be offered, appropriate indications for treatment, the pharmacological treatments and other interventions
that should be offered to specific patient groups, information
on self-management that should be provided to patients, how
the levels of healthcare systems should be integrated to ensure
seamless care, and how the quality of osteoporosis healthcare
services should be monitored and improved.
APCO’s goal is that all new or revised clinical practice
guidelines for prevention, diagnosis, and management of osteoporosis in the Asia-Pacific region will:
&
&
&

be consistent with the scope proposed in the Framework,
promote the standards of care recommended in the
Framework, and
recommend local benchmarking against the standards recommended in the Framework.

To achieve this, APCO members will identify opportunities in their individual countries and regions to share the
Framework with colleagues and organizations involved in
clinical practice guideline development. The clinical standards
will be distributed in a modular format that should allow easy
adoption at the individual health care facility, national or regional level.

Benchmarking and audit activities
Benchmarking against specific clinical standards is already
used to measure the performance of osteoporosis care.
Benchmarking of care for secondary prevention of fragility
fractures is a component of the IOF Capture the Fracture®
program [40], and of national fracture liaison service standards based on the 5IQ model [7–9]. Hip fracture registries,
that have been established in several countries, also enable
benchmarking of acute perioperative care and secondary fracture prevention after hip fracture [41–46].
After the Framework is published and it is disseminated,
audit against benchmarks derived from the Framework will be
undertaken at various healthcare system levels, ranging from
individual healthcare provider or primary care medical practice level to hospital units, groups of hospitals, regions, or
nations. The scale of activities can range from audit based
on one selected standard to audit against several standards.

Initially, APCO members will be invited to undertake
“pathfinder audits” in their hospitals to establish baseline
levels of adherence with selected standards, such as BMD
testing rates and osteoporosis treatment initiated during the
episode of care. Follow-up audits will be conducted 12
months later to measure effects of implementing the standards.

Recently established and emerging themes in
osteoporosis care
Several developments that significantly impact strategies for
the management of osteoporosis have recently been brought to
the forefront of medical management of osteoporosis.
Predictably, the 5IQ analysis found that these were either
not incorporated into existing guidelines or mentioned only
briefly. However, they have enormous implications and potential to change the treatment landscape of osteoporosis and
therefore need to be highlighted.
These include but are not limited to:
&

&
&
&

systematic integration of case identification and management at all levels of health systems, including acute care
services, when patients present with fractures (e.g.,
through FLSs),
stratification of individual fracture risk,
the role of sequential therapies, and
the use of health economics to inform intervention thresholds and indications for specific classes of osteoporosis
therapies.

Fracture liaison services
Up to 50% of patients with a hip fracture have already
sustained fractures at other skeletal sites during the previous
months or years [47, 48]. A prior fracture at any site is associated with a doubling of future fracture [49, 50] and mortality
[51] risks. Accordingly, these “signal” or “sentinel” fractures
should alert healthcare providers to the opportunity for secondary fracture prevention.
Over the past decade and a half, coordinated post-fracture
models of care have been designed to ensure that healthcare
providers consistently respond to the first fracture to prevent
the second and subsequent fractures [48]. These are generally
hospital-based, but involvement of primary care physicians is
also important to ensure continuity of care [52, 53].
Components of effective FLSs include multidisciplinary involvement, dedicated case managers and clinician champions,
regular assessment and follow-up, multifaceted interventions,
and patient education [54].
Fracture liaison service programs significantly increase
rates of BMD testing, initiation of osteoporosis treatment, adherence to treatment, and reduce refracture incidence and
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mortality rates, compared with usual care [54, 55]. They are
cost-effective in comparison with usual care or no treatment,
regardless of the program intensity or the country [55]. The
IOF strongly promotes the concept of FLSs through its global
Capture the Fracture® initiative [40]. This initiative has set an
international benchmark for FLSs by defining 13 globally
endorsed standards for service delivery.
Fracture liaison services in the Asia-Pacific and reference
to these in the extant guidelines
The number of FLSs in the Asia-Pacific region is rapidly
increasing. Analyses of indigenous fracture liaison programs
have been conducted in several countries and regions in the
Asia-Pacific region including Australia [56], China [57, 58],
Chinese Taipei [59], Hong Kong SAR [60], Singapore [61],
Japan [62–64], New Zealand [65], South Korea [66–69], and
Thailand [70]. In 2017, the fracture liaison service consensus
meeting held in Taipei concluded that the 13 Best Practice
Framework Standards of the IOF’s Capture the Fracture®
campaign [40] were generally applicable in the Asia-Pacific
region (albeit with minor modifications). As of 17 September
2020, 111 FLSs from the Asia-Pacific region are included on
the IOF Global Map of Best Practice (https://www.
capturethefracture.org/map-of-best-practice). Eighty-four
have been fully evaluated, of which 19 have been awarded a
Gold star. These include FLSs from Australia, Japan, New
Zealand, Singapore, Taiwan, and Thailand.
Despite this burgeoning interest, the 5IQ analysis revealed
that only four guidelines in the Asia-Pacific region advocated
the role of FLSs, suggesting that the crucial role of secondary
fracture prevention is still sadly under-recognized among
guideline developers and policy makers in the Asia-Pacific
[52]. Two recent initiatives are, however, expected to enable
more widespread adoption of FLSs in the region: the FLS tool
box for Asia-Pacific developed by the Asia-Pacific Bone
Academy Fracture Liaison Service Focus Group [71], and the
Capture the Fracture® Partnership launched by the IOF (https://
www.capturethefracture.org/capture-fracture-partnership),
which includes several countries in the Asia Pacific region.
Risk stratification
Upon the knowledge that “fractures beget fractures” [47, 49,
50] has subsequently come the understanding that the risk of a
subsequent fragility fracture is particularly acute immediately
after the sentinel or the index fracture and that this risk wanes
progressively with time [72–78]. This very high fracture risk
in the 1 to 2 years after the index fracture has been termed
“imminent risk” [79, 80] and appears to be age-dependent,
with the transient effect of increased risk being more evident
at older ages [76]. The ratio of 10-year fracture probability
after a recent fragility fracture to that after a fracture,

irrespective of its site or recency, has been termed the probability ratio or adjustment ratio. Probability ratios that provide
adjustments to conventional FRAX® estimates for recency of
sentinel fractures have now been derived, though how they
will be included in the FRAX® algorithm is still being debated [81].
Other factors can also contribute to, or result in, a very high
fracture risk. The simultaneous presence of multiple risk factors
(e.g., family history of fracture, glucocorticoid use) can additively contribute to fracture probabilities and shift fracture risk
categories to higher strata of risk [30]. Individuals have also
been somewhat arbitrarily designated as very high risk if they
have fractures while on approved osteoporosis therapy, have
multiple prevalent fractures or fractures while on drugs causing
skeletal harm such as glucocorticoids, have very low T-score
(e.g., < − 3.0), have high risk for falls or a history of falls, or
have a FRAX® probability for major osteoporosis fracture >
30%, or hip fracture > 4.5% over a 10-year period [82].
This concept of stratification of osteoporotic fracture risk
that may enable or guide the choice of therapeutic agent is
gaining traction globally. Those at higher risk may require initiation of treatment with more potent therapies such as an anabolic agent. For those at low risk, a decision will need to be
made on whether therapy with an anti-osteoporosis agent is
even indicated. Updated position papers and guidelines published by the European Society for Clinical and Economic
Aspects of Osteoporosis (ESCEO) and the International
Osteoporosis Foundation (IOF) [80] and by the American
Association of Clinical Endocrinologists (AACE) [82] provide
recommendations for this stratification of risk. The ESCEO/
IOF position paper applies age-specific thresholds to define
high versus very high risk, while the AACE guidelines suggest
an arbitrarily decided fixed threshold as well as the presence of
certain pre-defined risk factors as described previously [80, 82].
At a regional and national level, these recommendations
will have to be reviewed to determine the relevance to local
practices and to see whether they offer tangible benefits to
patients. Some challenges to implementation of these guidelines in the Asia-Pacific would need to be considered. The
FRAX® thresholds that are recommended in the AACE
guidelines are likely only applicable to the USA. While
FRAX® has been validated in many Asian countries, most
of them have not implemented specific intervention thresholds
for use yet. Recommendations also need to consider local
reimbursement criteria, which often dictate eligibility criteria
for pharmacological treatment options.
Sequential therapies in osteoporosis
Osteoporosis is a chronic condition. Therefore, patients with
osteoporosis need a long-term, personalized management plan,
with many patients requiring multiple anti-osteoporosis medications during their lifetime. The specific and individualized
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treatment plan traditionally has involved initiation of therapy
with an antiresorptive agent. Most of the extant guidelines in
the Asia-Pacific region also favor this approach. However, there
is evidence for a stronger anti-fracture efficacy of bone-forming
treatments compared to antiresorptive ones from two clinical
trials in patients with severe osteoporosis [83, 84] and for a
blunted/delayed BMD response to bone-forming treatment,
with prior antiresorptive use, though this effect somewhat depends on the potency of the antiresorptive agent [85–87].
In certain scenarios, a deleterious effect on BMD is seen in
patients previously treated with antiresorptive agents who are
then switched to an anabolic agent [88]. In contrast, sequential
therapy with an anabolic agent followed by an antiresorptive
agent appears largely to be associated with maintenance or
continued increase in BMD [88] and continued reduction in
fractures [84, 89].
This has resulted in increasing interest in sequential treatment with an anabolic agent given as first-line treatment in the
very-high-risk fracture patient, whose fracture risk needs to be
addressed quickly and in whom BMD needs to be improved
quickly and as much as possible. However, the fact that this
may not always be possible, due to restrictions in reimbursement criteria and limitations imposed by guidelines, should be
considered before advocating large-scale adoption of such
recommendations.

Health economics
Health economic analysis is playing an increasingly important
role to inform the relative value of osteoporosis therapies and
to help determine how best to allocate finite health care resources. The development of absolute fracture risk–based assessment and intervention thresholds has led also to the exploration of cost-effectiveness of interventions along the lines
of fracture probability. A significant body of evidence now
exists to show that anti-osteoporosis therapies are costeffective in women at high risk of fracture [90].
However, the cost-effectiveness of various pharmacological therapies is determined in part by the costs and benefits of
treatment. Intervention thresholds will also vary, since they
depend critically on country- and region-specific factors such
as reimbursement issues, health economic assessment, willingness to pay for healthcare, and access to DXA scanning.
Due to this vast heterogeneity in epidemiologic and economic
characteristics between countries, such thresholds should be
country-specific. In the USA, a 10-year absolute hip fracture
probability of 3% and its equivalent major osteoporotic fracture probability of 20% have been considered as cost-effective
intervention thresholds [39]. Various other major osteoporotic
fracture risk fixed intervention thresholds ranging from 7 to
15% have been deemed to be cost-effective in other countries
[91, 92]. In the UK, age-dependent FRAX®-based

intervention thresholds have been shown to provide clinically
appropriate access to treatment as well as to be cost-effective
[93].
Given the evidence supporting initial treatment of patients
at very high risk of fragility fracture with an anabolic agent
followed by consolidating the effect of these agents with
antiresorptive agents, health economic appraisals exploring
the cost-effectiveness of such sequential therapies are also
slowly emerging [94].
Health economic evaluation studies in osteoporosis are few
in the Asia-Pacific region. Robust studies have been conducted
in a few countries including Singapore [95], China [96, 97],
Japan [98, 99], and Australia [100]. These studies have
employed different modeling strategies and have explored
cost-effectiveness of fracture intervention thresholds as well
as of various osteoporosis medications. The varying results
obtained from these studies highlight the crucial differences in
economic, epidemiological, and clinical practice factors between the countries in the vast region that is the Asia-Pacific.

Conclusions
The APCO Framework represents the first consensus minimum standards of osteoporosis care, purpose-developed
by clinicians for the whole of the Asia-Pacific region.
Developing it through a comparative analysis of extant
guidelines in the Asia Pacific region and through the consensus of experts from diverse health care systems enables
the recommendations to be practical and relevant to the
unique needs of this vast and populous region. However,
publishing and disseminating the Framework is only half
the battle won. The success of the Framework will be
discernible only after the standards have been implemented throughout the region and its efficacy has been systematically measured.
The Framework provides accessible, clear, and feasible recommendations for osteoporosis care in the Asia Pacific region. It
is hoped that the Framework will inform national societies,
guideline development authorities, and health care policy makers
in the development of new guidelines and promote the revision
of existing guidelines. The principles and processes behind its
development can be translated and adapted to other regions of the
world that also face similar socioeconomic diversity and heterogeneity of healthcare resources. The implementation of the
Framework, or similar sets of standards of care inspired by it, is
thus expected to significantly reduce the burden of osteoporosis,
not only in the Asia Pacific region, but also globally.
Emerging concepts in osteoporosis care and technologies
should also be keenly followed and should be incorporated
into new and revised guidelines after careful deliberation on
their applicability to local health care practices.
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Appendix 1 Template for extracting data
from clinical practice guidelines (modified
5IQ model)

Publication information and format
1. Country/region
2. Sponsor organization
3. Year
4. Number of pages
5. Review date
6. Guideline published in English (Yes/No)
7. Corresponding author (Yes/No)
8. Does the guideline include a flowchart/algorithm?
Identification
1. Male, female, both male and female
2. Individuals who have sustained fragility fractures

a. Age threshold
b. Fracture types evaluated
c. Other comments relating to secondary fracture
prevention
3. Individuals taking medicines to manage other conditions which are associated with bone loss a. Androgen deprivation therapy
and/or increased fracture risk:[10]
b. Anticoagulants
c. Anticonvulsants
d. Aromatase inhibitors
e. Calcineurin inhibitors
f. Glucocorticoids
g. Medroxyprogesterone acetate
h. Proton pump inhibitors
i. Selective serotonin reuptake inhibitors
j. Thiazolidinediones
k. Other medicines
4. Conditions associated with bone loss and/or increased fracture risk:[10]

5. Other risk factors

a. Chronic obstructive pulmonary disease
b. Diabetes
c. Diseases of malabsorption
d. Dementia
e. Rheumatoid arthritis
f. HIV
g. Multiple myeloma
h. Untreated/uncontrolled hyperthyroidism
i. Other conditions
a. Age 70 years or over
b. Early menopause
c. Excessive alcohol intake
e. Family history
f. Height loss
g. Low body mass index/weight
h. Prolonged immobility
i. Smoking
j. Other risk factors
k. Other comments on identification

Osteoporos Int
(continued)
Publication information and format
Investigation
1. BMD testing, if available
2. Fracture risk calculators

3. Vertebral fracture assessment by X-Ray or DXA
4. Falls risk assessment
5. Blood biochemistry

a. FRAX®
b. Garvan
c. IOF 1-minute test
d. KKOS
e. OSTA
f. MORES
g. QFracture
h. SCORE

a. Alkaline phosphatase
b. Calcium
c. Creatinine
d. Osteocalcin
e. uNTX
g. P1NP
h. PTH
i. Vitamin D
j. Other assays

6. Referral to specialist
Information
1. Information on calcium intake
2. Information relating to sun exposure
3. Information relating to osteoporosis and fracture risk
4. Information relating to exercise
5. Other information
Intervention
1. Which patient groups are indicated for treatment?

a. Hip fracture
b. Vertebral fracture
c. Non-hip, non-vertebral fracture
d. BMD T-Score ≤ –2.5 SD
e. Osteopenia + FRAX ≥3% Hip or ≥ 20% MOF
f. Osteopenia + RFs or eligible by OSTA or SCORE
g. Osteopenia + ≥10 years postmenopausal
h. FRAX or Garvan ≥3% Hip or ≥ 20% MOF
i. Eligible by OSTA, MORES or SCORE
j. QCT <80 mg/cm3

2. Which treatment options are recommended?

k. Height loss >4 cm
l. Androgen deprivation therapy use
m. Aromatase inhibitor use
n. Glucocorticoid use
a. Bisphosphonates (oral, IV)
b. Calcium
c. HRT
d. Monoclonal antibodies (denosumab, romosozumab)
e. Parathyroid hormone analogues (abaloparatide,
teriparatide)
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(continued)
Publication information and format
f. Selective estrogen receptor modulators (raloxifene.
tamoxifen. toremifene)
g. Vitamin D
h. Other treatment options
3. Are recommendations made on monitoring treatment?
4. Are recommendations made on treatment duration?
5. Are recommendations made on checking adherence with treatment?
6. Comments on side effects
7. Comments on referral to falls prevention programs
8. Comments relating to other interventions
Integration
1. Are recommendations made to provide the patient with a long-term management plan?
2. Are recommendations made to provide the patient’s primary care provider with a long-term management plan?
Quality
1. Does the guideline advocate audit of care provision against clinical care standards?
2. Does the guideline advocate healthcare providers maintain ongoing professional medical education relating to osteoporosis?

Appendix 2 Delphi Round 1 questionnaire
toward consensus on clinical standards
for osteoporosis

Domain 1: Notable findings from the 5IQ Comparative analysis of osteoporosis clinical guidelines from across the Asia Pacific region
This domain of the questionnaire includes a series of open-ended questions which invite you to share your opinions on the most notable findings of the
5IQ analysis report.
5IQ item
Question
Options
Identification Considering the groups of individuals that the various guidelines recommend should be identified for [Free text]
bone health assessment, what are the most notable findings in the analysis? (You can indicate more
than one)
Investigation Considering the investigations that the various guidelines recommend should be undertaken, what are [Free text]
the most notable findings in the analysis?
Information Considering the types of information that should be imparted to patients to engage them in their care, [Free text]
which are the most notable points identified by the analysis in your view?
Intervention Considering the indications for treatment that are advocated, what are the most notable findings
[Free text]
identified by the analysis in your view?
Considering the pharmacological treatments for specific patient groups identified by the analysis, what [Free text]
are the most notable findings in your view?
Considering the findings of the analysis related to falls prevention, what are the most notable in your [Free text]
view?
Integration
Considering how integration should occur between primary and secondary care, what are the most
[Free text]
notable findings identified by the analysis in your view?
Quality
Considering the findings of the 5IQ Comparative analysis related to quality metrics, what are the most [Free text]
notable findings in your view?
Domain 2: How should the Framework be structured?
How do you envisage the Framework being structured? Would you like to have it as a simple list of standards or have [Free text]
several levels of attainment (i.e. Level 1, Level 2, Level 3)?
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(continued)
Domain 3: What clinical standards are required?
This domain seeks your opinions on what specific aspects of care merit having a clinical standard. We invite you to rate the importance or not of having
particular standards and invite you to add any comments as free text.
5IQ item
Question
Options
Identification How important is it to have a standard relating to identification of individuals with fragility fractures? Extremely important
Very important
Somewhat important
Not so important
Not at all important
How important is it to have a standard relating to identification of individuals with common risk factors Extremely important
for osteoporosis (e.g. age 70 years or over, early menopause, excessive alcohol intake, family history, Very important
height loss, low body mass index/weight, prolonged immobility, smoking)?
Somewhat important
Not so important
Not at all important
How important is it to have a standard relating to identification of individuals who take medicines
Extremely important
associated with bone loss and/or increased fracture risk?
Very important
Somewhat important
Not so important
Not at all important
How important is it to have a standard relating to identification of individuals with conditions associated Extremely important
with bone loss and/or increased fracture risk?
Very important
Somewhat important
Not so important
Not at all important
Investigation How important is it to have a standard relating to biochemical investigations of individuals undergoing Extremely important
assessment?
Very important
Somewhat important
Not so important
Not at all important
How important is it to have a standard relating to BMD testing of individuals undergoing assessment? Extremely important
Very important
Somewhat important
Not so important
Not at all important
How important is it to have a standard relating to use of risk assessment tools for individuals undergoing Extremely important
assessment?
Very important
Somewhat important
Not so important
Not at all important
How important is it to have a standard relating to How important is it to have a standard relating to
Extremely important
vertebral fracture assessment for individuals undergoing assessment? for individuals undergoing
Very important
assessment?
Somewhat important
Not so important
Not at all important
How important is it to have a standard relating to falls risk assessment for individuals undergoing
Extremely important
assessment?
Very important
Somewhat important
Not so important
Not at all important
How important is it to have a standard relating to scenarios when referral to a specialist is required? Extremely important
Very important
Somewhat important
Not so important
Not at all important
Information How important is it to have a standard relating to what information should be imparted to patients to Extremely important
engage them in their care (e.g. information on calcium intake, sun exposure, the relationship between Very important
osteoporosis and fracture risk, exercise and other information)?
Somewhat important
Not so important
Not at all important
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(continued)
Intervention

Integration

The 5IQ analysis identified a broad range of indications for treatment, as listed below. In your opinion,
which of the following indications for treatment should feature in osteoporosis clinical guidelines?
Please indicate in priority order (where number 1 is the highest priority). Only provide rankings for those
indications which you believe should be included.
[ ] Hip fracture
[ ] Vertebral fracture
[ ] Non-hip, non-vertebral fracture
[ ] BMD T-Score ≤ –2.5 SD
[ ] Osteopenia + FRAX® ≥3% Hip or ≥ 20% MOF
[ ] Osteopenia + RFs or eligible by OSTA or SCORE
[ ] Osteopenia + ≥10 years postmenopausal
[ ] FRAX® or Garvan ≥3% Hip or ≥ 20% MOF
[ ] Eligible by OSTA, MORES or SCORE
[ ] QCT <80 mg/cm3
[ ] Height loss >4 cm
[ ] Androgen deprivation therapy use
[ ] Aromatase inhibitor use
[ ] Glucocorticoid use
[ ] Country-specific thresholds
How important is it to have a standard relating to which pharmacological treatments should be
recommended for specific patient groups?

[Select items and rank
according to priority]

Extremely important
Very important
Somewhat important
Not so important
Not at all important
How important is it to have a standard relating to which non-pharmacological interventions should be Extremely important
recommended?
Very important
Somewhat important
Not so important
Not at all important
How important is it to have a standard relating to description of side effects associated with
Extremely important
pharmacological treatments?
Very important
Somewhat important
Not so important
Not at all important
How important is it to have a standard relating to monitoring of treatment with pharmacologic agents? Extremely important
Very important
Somewhat important
Not so important
Not at all important
How important is it to have a standard relating to duration of treatment with pharmacologic agents? Extremely important
Very important
Somewhat important
Not so important
Not at all important
How important is it to have a standard relating to treatment adherence with pharmacologic agents? Extremely important
Very important
Somewhat important
Not so important
Not at all important
How important is it to have a standard relating to referral of patients to falls prevention programmes? Extremely important
Very important
Somewhat important
Not so important
Not at all important
How important is it to have a standard relating to provision of a long-term management plan to the
Extremely important
patients and/or primary care provider?
Very important
Somewhat important
Not so important
Not at all important
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(continued)
Quality

How important is it to have a standard relating to what quality metrics should be in place to assess
adherence with guidelines-based care?

General
Do you have any other comments related to the development of the Framework clinical standards?

Extremely important
Very important
Somewhat important
Not so important
Not at all important
[Free text]

Appendix 3 The APCO Framework

Clinical standards

1

2

3

4

5

6

7
8

9

Levels of attainment
(where applicable)

Men and women who sustain a fragility fracture should be systematically 1. Individuals who sustain hip fractures should be identified.
and proactively identified to undergo assessment of bone health and, 2: Individuals who sustain hip and/or clinical vertebral fractures should
where appropriate, falls risk.
be identified.
3: Individuals who sustain hip, clinical and/or morphometric vertebral,
and/or non-hip, non-vertebral major osteoporotic fractures should be
identified.
Men and women with common risk factors for osteoporosis should be
proactively identified to undergo assessment of bone health and,
where appropriate, falls risk. A sex-specific age threshold for
assessment should be determined for each country or region and
should be included in new or revised osteoporosis clinical guidelines.
Men and women who take medicines that are associated with bone loss
and/or increased fracture risk should be proactively identified to
undergo assessment of bone health and, where appropriate, falls risk.
A commentary should be included in new or revised osteoporosis
clinical guidelines to highlight commonly used medicines that are
associated with bone loss and/or increased fracture risk.
Men and women who have conditions associated with bone loss and/or
increased fracture risk should be proactively identified to undergo
assessment of bone health. A commentary should be included in new
or revised osteoporosis clinical guidelines to highlight common
prevalent conditions in the country or region.
The use of country-specific (if available) fracture risk assessment tools
(e.g. FRAX®, Garvan, etc.) or osteoporosis screening tools (e.g.
OSTA) should be a standard component of investigation of an
individual’s bone health and prediction of future fracture risk and/or
osteoporosis risk.
Assessment for presence of vertebral fracture(s) either by X-ray (or other 1. Individuals presenting with clinical vertebral fractures should undergo
radiological investigations such as CT or MRI), or by DXA-based
assessment for osteoporosis.
VFA should be a standard component of investigation of osteoporosis 2. Individuals with incidentally detected vertebral fractures on X-ray
and prediction of future fracture risk.
and/or other radiological investigations should be assessed for
osteoporosis.
3. Individuals being a ssessed for osteoporosis should undergo spinal
imaging with X-ray or other appropriate radiological modalities, or
with DXA-based VFA.
A falls risk assessment should be a standard component of investigation
of an individual’s future fracture risk.
In order to engage individuals in their own care, information should be
provided on calcium and vitamin D intake, sun exposure, exercise, and
the relationship between osteoporosis and fracture risk.
The decision to treat with osteoporosis-specific therapies and the choice
of therapy should be informed as much as possible by country-specific
and cost-effective intervention thresholds. Intervention thresholds that
can be considered include:
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(continued)
Clinical standards

10

11

12

13

14

15

16

Levels of attainment
(where applicable)

• History of fragility fracture
• BMD T-Score ≤ –2.5 S.D.
• High fracture risk as assessed by country-specific intervention
thresholds.
New or revised osteoporosis clinical guidelines should include a
commentary on the common side effects of pharmacological
treatments that are recommended in the guidelines.
New or revised osteoporosis clinical guidelines should provide a
commentary on monitoring of pharmacological treatments. This could
include, e.g. the role of biochemical markers of bone turnover and
bone mineral density measurement.
New or revised osteoporosis clinical guidelines should provide a
commentary on the duration of pharmacological treatments that are
recommended in the guidelines. This should include a discussion on
the appropriate order of sequential treatment with available therapies
and the role of ‘drug holidays’.
Assessment of adherence to pharmacological treatments that are
recommended in new or revised osteoporosis clinical guidelines
should be undertaken on an ongoing basis after initiation of therapy,
and appropriate corrective action be taken if treated individuals have
become non-adherent.
New and revised osteoporosis clinical guidelines should provide a
commentary on recommended non-pharmacological interventions,
such as exercise and nutrition (including dietary calcium intake) and
other non-pharmacological interventions (e.g. hip protectors).
In collaboration with the patient, the treating clinician (hospital specialist
and/or primary care provider) should develop a long-term
management plan, that, provides recommendations on
pharmacological and non-pharmacological interventions to improve
bone health and, where appropriate, measures to reduce falls risk.
New or revised osteoporosis clinical guidelines should provide a
1. Conduct a local ‘pathfinder audit’ in a hospital or primary care practice
commentary on what quality metrics should be in place to assess
to assess adherence to APCO Framework Clinical Standards 1–9, 13
adherence with guideline-based care.
and 15.
2. Contribute to a local fracture/osteoporosis registry.
3. Contribute to a fracture/osteoporosis registry for your country or
region.

Open Access This article is licensed under a Creative Commons

Attribution-NonCommercial 4.0 International License, which permits
any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the
original author(s) and the source, provide a link to the Creative Commons
licence, and indicate if changes were made. The images or other third
party material in this article are included in the article's Creative
Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence
and your intended use is not permitted by statutory regulation or exceeds
the permitted use, you will need to obtain permission directly from the
copyright holder. To view a copy of this licence, visit http://
creativecommons.org/licenses/by-nc/4.0/.

References
1.

The Royal Australian College of General Practitioners,
Osteoporosis Australia (2017) Osteoporosis prevention, diagnosis
and management in postmenopausal women and men over 50
years of age, 2nd edn. RACGP, East Melbourne

2.

Osteoporosis and Bone Mineral Disease Branch of Chinese
Medical Association (2017) Guidelines for the diagnosis and
treatment of primary osteoporosis (2017). Chin J Osteo Bone
Miner Res 10:413–444
3. Workgroup of 2018 China Guideline for the Diagnosis and
Treatment of Senile Osteoporosis, Osteoporosis Society of
China Association of Gerontology and Geriatrics, Ma Y et al
(2018) 2018 China guideline for the diagnosis and treatment of
senile osteoporosis [in Chinese]. Chin J Health Manage 12:484–
509
4. Osteoporosis Group Orthopaedic Branch Chinese Medical
Association, Liu Q, Cao L et al (2017) Guidelines for the diagnosis and treatment of osteoporotic fractures [in Chinese]. Chin J
Orthop 37:1–10
5. OSHK Task Group for Formulation of OSHK Guideline for
Clinical Management of Postmenopausal Osteoporosis in Hong
Kong, Ip TP, Cheung SK et al (2013) The Osteoporosis Society of
Hong Kong (OSHK): 2013 OSHK guideline for clinical management of postmenopausal osteoporosis in Hong Kong. Hong Kong
Med J 19(Suppl 2):1–40
6. Huang Z, Fang Y, Wu Z et al (2017) 2017 Consensus and guidelines for the prevention and treatment of adult osteoporosis in
Taiwan. Taiwanese Osteoporosis Association, Taipei

Osteoporos Int
7.

8.

9.

10.

11.

12.

13.

14.

15.

16.

17.

18.

19.

20.

21.

22.

23.

24.

Singh M, Harinarayan CV, Marwah R, Sahay R, Kalra S,
Babhulkar S (2020) Clinical practice guidelines on postmenopausal osteoporosis: An executive summary and recommendations - Update 2019. Indian Menopause Society, Hyderabad
Bhadada SK (2020) Indian society for bone and mineral research
guidelines 2020. Indian Society for Bone and Mineral Research,
New Delhi
Setyohadi B, Hutagalung EUHU, Frederik Adam JM et al (2012)
Summary of the Indonesian guidelines for diagnosis and management of osteoporosis. JAFES 27:147
Orimo H (2015) Japanese 2015 guidelines for the prevention and
treatment of osteoporosis [in Japanese]. Japan Osteoporosis
Society, The Japanese Society for Bone and Mineral Research &
Japan Osteoporosis Foundation, Tokyo
Chan SP, Yeap SS, Lee EGM, Chee W, Hew FL, Lee JK, Lim
HH, Damodaran P, Mumtaz M (2015) Clinical guidance on management of osteoporosis, 2nd edn. Malaysian Osteoporosis
Society, Academy of Medicine & Ministry of Health, Malaysia,
Petaling Jaya
Latt TS, Aye TT, Ko K, Myint T, Hliang NN, Thaung M, Chit TT
(2012) Myanmar clinical practice guidelines for osteoporosis.
JAFES 27:151–155
Gilchrist N, Reid IR, Sankaran S, Kim D, Drewry A, Toop L,
McClure F (2017) Guidance on the diagnosis and management
of osteoporosis in New Zealand. Osteoporosis New Zealand,
Wellington
Li-Yu J, Perez EC, Canete A, Bonifacio L, Llamado LQ, Martinez
R, Lanzon A, Sison M, Osteoporosis Society of Philippines
Foundation Inc, Philippine Orthopedic Association Clinical
Practice Guidelines Task Force Committee on Osteoporosis
(2011) Consensus statements on osteoporosis diagnosis, prevention, and management in the Philippines. Int J Rheum Dis 14:223–
238
Chandran M, Ang SB, Au L et al (2018) Appropriate care guide:
osteoporosis identification and management in primary care.
Ministry of Health, Singapore
Yoon HG, Jung HY, Yoon BG (2019) KSBMR physician's guide
for osteoporosis [in Korean]. Korean Society for Bone and
Mineral Research, Seoul
Songpatanasilp T, Sritara C, Kittisomprayoonkul W et al (2016)
Thai Osteoporosis Foundation (TOPF) position statements on
management of osteoporosis. Osteoporos Sarcopenia 2:191–207
Vietnam Rheumatology Association (2016) Guidelines for the
diagnosis and treatment of osteoporosis [in Vietnamese].
Vietnam Rheumatology Association, Hanoi
Bhadada SK (2020) Indian Society for Bone and Mineral
Research guidelines 2020. Indian Society for Bone and Mineral
Research, New Delhi
Setyohadi B, Hutagalung EUHU, Frederik Adam JM et al (2012)
Summary of the Indonesian guidelines for diagnosis and management of osteoporosis. JAFES 27:147–150
Orimo H (2015) [Japanese 2015 guidelines for the prevention and
treatment of osteoporosis] [in Japanese]. Japan Osteoporosis
Society, The Japanese Society for Bone and Mineral Research &
Japan Osteoporosis Foundation, Tokyo
Chan SP, Yeap SS, Lee EGM, Chee W, Hew FL, Lee JK, Lim
HH, Damodaran P, Mumtaz M (2015) Clinical guidance on management of osteoporosis, 2nd edn. Malaysian Osteoporosis
Society, Academy of Medicine & Ministry of Health, Malaysia,
Petaling Jaya
Latt TS, Aye TT, Ko K, Myint T, Hliang NN, Thaung M, Chit TT
(2012) Myanmar clinical practice guidelines for osteoporosis.
JAFES 27:151–155
Gilchrist N, Reid IR, Sankaran S, Kim D, Drewry A, Toop L,
McClure F (2017) Guidance on the diagnosis and management

of osteoporosis in New Zealand. Osteoporosis New Zealand,
Wellington
25. Li-Yu J, Perez EC, Canete A, Bonifacio L, Llamado LQ, Martinez
R, Lanzon A, Sison M, Osteoporosis Society of Philippines
Foundation Inc, Philippine Orthopedic Association Clinical
Practice Guidelines Task Force Committee on Osteoporosis
(2011) Consensus statements on osteoporosis diagnosis, prevention, and management in the Philippines. Int J Rheum Dis 14:223–
238
26. Chandran M, Ang SB, Au L et al (2018) Appropriate care guide:
osteoporosis identification and management in primary care.
Ministry of Health, Singapore
27. Yoon HG, Jung HY, Yoon BG (2019) KSBMR physician’s guide
for osteoporosis] [in Korean]. Korean Society for Bone and
Mineral Research, Seoul
28. Songpatanasilp T, Sritara C, Kittisomprayoonkul W, Chaiumnuay
S, Nimitphong H, Charatcharoenwitthaya N, Pongchaiyakul C,
Namwongphrom S, Kitumnuaypong T, Srikam W, Dajpratham
P, Kuptniratsaikul V, Jaisamrarn U, Tachatraisak K,
Rojanasthien S, Damrongwanich P, Wajanavisit W, Pongprapai
S, Ongphiphadhanakul B, Taechakraichana N (2016) Thai
Osteoporosis Foundation (TOPF) position statements on management of osteoporosis. Osteoporos Sarcopenia 2:191–207
29. Vietnam Rheumatology Association (2016) Guidelines for the
diagnosis and treatment of osteoporosis] [in Vietnamese].
Vietnam Rheumatology Association, Hanoi
30. Kanis JA, Johansson H, Harvey NC, McCloskey EV (2018) A
brief history of FRAX. Arch Osteoporos 13:118
31. Koh LK, Sedrine WB, Torralba TP, Kung A, Fujiwara S, Chan
SP, Huang QR, Rajatanavin R, Tsai KS, Park HM, Reginster JY,
Osteoporosis Self-Assessment Tool for Asians (OSTA) Research
Group (2001) A simple tool to identify asian women at increased
risk of osteoporosis. Osteoporos Int 12:699–705
32. Nguyen ND, Frost SA, Center JR, Eisman JA, Nguyen TV (2008)
Development of prognostic nomograms for individualizing 5-year
and 10-year fracture risks. Osteoporos Int 19:1431–1444
33. International Osteoporosis Foundation IOF Risk Check. IOF.
https://www.iofbonehealth.org/iof-one-minute-osteoporosis-risktest
34. Pongchaiyakul C, Nguyen ND, Pongchaiyakul C, Nguyen TV
(2004) Development and validation of a new clinical risk index
for prediction of osteoporosis in Thai women. J Med Assoc Thail
87:910–916
35. Shepherd AJ, Cass AR, Carlson CA, Ray L (2007) Development
and internal validation of the male osteoporosis risk estimation
score. Ann Fam Med 5:540–546
36. Hippisley-Cox J, Coupland C (2009) Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores. Bmj 339:b4229
37. Hippisley-Cox J, Coupland C (2012) Derivation and validation of
updated QFracture algorithm to predict risk of osteoporotic fracture in primary care in the United Kingdom: prospective open
cohort study. Bmj 344:e3427
38. Cadarette SM, Jaglal SB, Murray TM (1999) Validation of the
simple calculated osteoporosis risk estimation (SCORE) for patient selection for bone densitometry. Osteoporos Int 10:85–90
39. Tosteson AN, Melton LJ 3rd, Dawson-Hughes B, Baim S, Favus
MJ, Khosla S, Lindsay RL (2008) Cost-effective osteoporosis
treatment thresholds: the United States perspective. Osteoporos
Int 19:437–447
40. Akesson K, Marsh D, Mitchell PJ, McLellan AR, Stenmark J,
Pierroz DD, Kyer C, Cooper C (2013) Capture the Fracture: a best
practice framework and global campaign to break the fragility
fracture cycle. Osteoporos Int 24:2135–2152
41. Kristensen PK, Rock ND, Christensen HC, Pedersen AB (2020)
The Danish Multidisciplinary Hip Fracture Registry 13-year

Osteoporos Int
results from a population-based cohort of hip fracture patients.
Clin Epidemiol 12:9–21
42. National Quality Registers [Sweden] (2019) National Quality Registry
for Hip Fracture Patients and Treatment (RIKSHÖFT). http://
kvalitetsregister.se/englishpages/findaregistry/registerarkivenglish/
nationalqualityregistryforhipfracturepatientsandtreatmentrikshoft.
2402.html Accessed Nov 2020
43. Australian and New Zealand Hip Fracture Registry (2019)
Australian and New Zealand Hip Fracture Registry [website].
http://www.anzhfr.org/ Accessed Nov 2020
44. Gjertsen JE, Engesaeter LB, Furnes O, Havelin LI, Steindal K,
Vinje T, Fevang JM (2008) The Norwegian Hip Fracture
Register: experiences after the first 2 years and 15,576 reported
operations. Acta Orthop 79:583–593
45. Alarcon T, Ojeda-Thies C, Sáez-López P, Gomez-Campelo P,
Navarro-Castellanos L, Otero-Puime A, González-Montalvo JI
(2020) Usefulness of a national hip fracture registry to evaluate
the profile of patients in whom antiosteoporotic treatment is prescribed following hospital discharge. Osteoporos Int 31:1369–
1375
46. Neuburger J, Currie C, Wakeman R, Tsang C, Plant F, De Stavola
B, Cromwell DA, van der Meulen J (2015) The impact of a national clinician-led audit initiative on care and mortality after hip
fracture in England: an external evaluation using time trends in
non-audit data. Med Care 53:686–691
47. Edwards BJ, Bunta AD, Simonelli C, Bolander M, Fitzpatrick LA
(2007) Prior fractures are common in patients with subsequent hip
fractures. Clin Orthop Relat Res 461:226–230
48. McLellan AR, Reid DM, Forbes K, Reid R, Campbell C, Gregori
A, Raby N, Simpson A (2004) Effectiveness of strategies for the
secondary prevention of osteoporotic fractures in scotland. CEPS:
99/03. NHS Quality Improvement Scotland, Glasgow
49. Kanis JA, Johnell O, De Laet C et al (2004) A meta-analysis of
previous fracture and subsequent fracture risk. Bone 35:375–382
50. Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA, Berger M
(2000) Patients with prior fractures have an increased risk of future
fractures: a summary of the literature and statistical synthesis. J
Bone Miner Res 15:721–739
51. Bliuc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA, Center
JR (2009) Mortality risk associated with low-trauma osteoporotic
fracture and subsequent fracture in men and women. Jama 301:
513–521
52. Chan DD, Chang LY, Akesson KE et al (2018) Consensus on best
practice standards for fracture liaison service in the Asia-Pacific
region. Arch Osteoporos 13:59
53. Walters S, Khan T, Ong T, Sahota O (2017) Fracture liaison services: improving outcomes for patients with osteoporosis. Clin
Interv Aging 12:117–127
54. Wu CH, Chen CH, Chen PH, Yang JJ, Chang PC, Huang TC,
Bagga S, Sharma Y, Lin RM, Chan DC (2018) Identifying characteristics of an effective fracture liaison service: systematic literature review. Osteoporos Int 29:1023–1047
55. Wu CH, Tu ST, Chang YF, Chan DC, Chien JT, Lin CH, Singh S,
Dasari M, Chen JF, Tsai KS (2018) Fracture liaison services improve outcomes of patients with osteoporosis-related fractures: a
systematic literature review and meta-analysis. Bone 111:92–100
56. Australian and New Zealand Bone and Mineral Society (2016)
Secondary fracture prevention program initiative: resource 1 –
secondary fracture prevention program resource pack. Australian
and New Zealand Bone and Mineral Society, Sydney
57. Wang O, Hu Y, Gong S, Xue Q, Deng Z, Wang L, Liu H, Tang H,
Guo X, Chen J, Jia X, Xu Y, Lan L, Lei C, Dong H, Yuan G, Fu Q,
Wei Y, Xia W, Xu L (2015) A survey of outcomes and management of patients post fragility fractures in China. Osteoporos Int
26:2631–2640

58.

Tian M, Gong X, Rath S, Wei J, Yan LL, Lamb SE, Lindley RI,
Sherrington C, Willett K, Norton R (2016) Management of hip
fractures in older people in Beijing: a retrospective audit and comparison with evidence-based guidelines and practice in the UK.
Osteoporos Int 27:677–681
59. Chang LY, Tsai KS, Peng JK, Chen CH, Lin GT, Lin CH, Tu ST,
Mao IC, Gau YL, Liu HC, Niu CC, Hsieh MH, Chien JT, Hung
WC, Yang RS, Wu CH, Chan DC (2018) The development of
Taiwan Fracture Liaison Service network. Osteoporos Sarcopenia
4:47–52
60. Leung KS, Yuen WF, Ngai WK, Lam CY, Lau TW, Lee KB, Siu
KM, Tang N, Wong SH, Cheung WH (2017) How well are we
managing fragility hip fractures? A narrative report on the review
with the attempt to setup a Fragility Fracture Registry in Hong
Kong. Hong Kong Med J 23:264–271
61. Chandran M, Tan MZ, Cheen M, Tan SB, Leong M, Lau TC
(2013) Secondary prevention of osteoporotic fractures–an
“OPTIMAL” model of care from Singapore. Osteoporos Int 24:
2809–2817
62. Hagino H, Sawaguchi T, Endo N, Ito Y, Nakano T, Watanabe Y
(2012) The risk of a second hip fracture in patients after their first
hip fracture. Calcif Tissue Int 90:14–21
63. Baba T, Hagino H, Nonomiya H, Ikuta T, Shoda E, Mogami A,
Sawaguchi T, Kaneko K (2015) Inadequate management for secondary fracture prevention in patients with distal radius fracture by
trauma surgeons. Osteoporos Int 26:1959–1963
64. Iba K, Dohke T, Takada J, Sasaki K, Sonoda T, Hanaka M,
Miyano S, Yamashita T (2018) Improvement in the rate of inadequate pharmaceutical treatment by orthopaedic surgeons for the
prevention of a second fracture over the last 10 years. J Orthop Sci
23:127–131
65. Braatvedt G, Wilkinson S, Scott M, Mitchell P, Harris R (2017)
Fragility fractures at Auckland City Hospital: we can do better.
Arch Osteoporos 12:64
66. Kim SR, Park YG, Kang SY, Nam KW, Park YG, Ha YC (2014)
Undertreatment of osteoporosis following hip fractures in jeju cohort study. J Bone Metab 21:263–268
67. Kim SC, Kim MS, Sanfélix-Gimeno G et al (2015) Use of osteoporosis medications after hospitalization for hip fracture: a crossnational study. Am J Med 128:519–526.e511
68. Yu YM, Lee JY, Lee E (2017) Access to anti-osteoporosis medication after hip fracture in Korean elderly patients. Maturitas 103:
54–59
69. Jung Y, Ko Y, Kim HY, Ha YC, Lee YK, Kim TY, Choo DS,
Jang S (2019) Gender differences in anti-osteoporosis drug treatment after osteoporotic fractures. J Bone Miner Metab 37:134–
141
70. Angthong C, Rodjanawijitkul S, Samart S, Angthong W (2013)
Prevalence of bone mineral density testing and osteoporosis management following low- and high-energy fractures. Acta Orthop
Traumatol Turc 47:318–322
71. Ebeling PR, Chan DC, Lau TC, Lee JK, Songpatanasilp T, Wong
SH, Hew FL, Sethi R, Williams M (2020) Secondary prevention
of fragility fractures in Asia Pacific: an educational initiative.
Osteoporos Int 31:805–826
72. Johnell O, Oden A, Caulin F, Kanis JA (2001) Acute and longterm increase in fracture risk after hospitalization for vertebral
fracture. Osteoporos Int 12:207–214
73. Nymark T, Lauritsen JM, Ovesen O, Röck ND, Jeune B (2006)
Short time-frame from first to second hip fracture in the Funen
County Hip Fracture Study. Osteoporos Int 17:1353–1357
74. Giangregorio LM, Leslie WD (2010) Time since prior fracture is a
risk modifier for 10-year osteoporotic fractures. J Bone Miner Res
25:1400–1405
75. Roux C, Briot K (2017) Imminent fracture risk. Osteoporos Int 28:
1765–1769

Osteoporos Int
76.

Johansson H, Siggeirsdóttir K, Harvey NC, Odén A, Gudnason V,
McCloskey E, Sigurdsson G, Kanis JA (2017) Imminent risk of
fracture after fracture. Osteoporos Int 28:775–780
77. Bonafede M, Shi N, Barron R, Li X, Crittenden DB, Chandler D
(2016) Predicting imminent risk for fracture in patients aged 50 or
older with osteoporosis using US claims data. Arch Osteoporos
11:26
78. Deloumeau A, Moltó A, Roux C, Briot K (2017) Determinants of
short term fracture risk in patients with a recent history of lowtrauma non-vertebral fracture. Bone 105:287–291
79. Kanis JA, Johansson H, Odén A, Harvey NC, Gudnason V,
Sanders KM, Sigurdsson G, Siggeirsdottir K, Fitzpatrick LA,
Borgström F, McCloskey EV (2018) Characteristics of recurrent
fractures. Osteoporos Int 29:1747–1757
80. Kanis JA, Harvey NC, McCloskey E, Bruyère O, Veronese N,
Lorentzon M, Cooper C, Rizzoli R, Adib G, al-Daghri N,
Campusano C, Chandran M, Dawson-Hughes B, Javaid K, Jiwa
F, Johansson H, Lee JK, Liu E, Messina D, Mkinsi O, Pinto D,
Prieto-Alhambra D, Saag K, Xia W, Zakraoui L, Reginster JY
(2020) Algorithm for the management of patients at low, high
and very high risk of osteoporotic fractures. Osteoporos Int 31:
1–12
81. Kanis J, Johansson H, Harvey N, Gudnason V, Sigurdsson G,
Siggeirsdóttir K, Lorentzon M, Liu E, Vandenput L, McCloskey
E (2020) Adjusting conventional FRAX estimates of fracture
probability according to the recency of sentinel fractures.
Osteoporos Int 31:1817–1828
82. Camacho PM, Petak SM, Binkley N, Diab DL, Eldeiry LS,
Farooki A, Harris ST, Hurley DL, Kelly J, Lewiecki EM,
Pessah-Pollack R, McClung M, Wimalawansa SJ, Watts NB
(2020) American Association of Clinical Endocrinologists/
American College of Endocrinology clinical practice guidelines
for the diagnosis and treatment of postmenopausal osteoporosis –
2020 update. Endocr Pract 26:1–46
83. Kendler DL, Marin F, Zerbini CAF, Russo LA, Greenspan SL,
Zikan V, Bagur A, Malouf-Sierra J, Lakatos P, FahrleitnerPammer A, Lespessailles E, Minisola S, Body JJ, Geusens P,
Möricke R, López-Romero P (2018) Effects of teriparatide and
risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, doubledummy, randomised controlled trial. Lancet 391:230–240
84. Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M,
Thomas T, Maddox J, Fan M, Meisner PD, Grauer A (2017)
Romosozumab or alendronate for fracture prevention in women
with osteoporosis. N Engl J Med 377:1417–1427
85. Ettinger B, San Martin J, Crans G, Pavo I (2004) Differential
effects of teriparatide on BMD after treatment with raloxifene or
alendronate. J Bone Miner Res 19:745–751
86. Miller PD, Delmas PD, Lindsay R, Watts NB, Luckey M, Adachi
J, Saag K, Greenspan SL, Seeman E, Boonen S, Meeves S, Lang
TF, Bilezikian JP, for the Open-label Study to Determine How
Pr i o r Th e r a p y w i t h A l e n d r o n a t e o r R i s e d r o n a t e i n
Postmenopausal Women with Osteoporosis Influences the
Clinical Effectiveness of Teriparatide Investigators (2008) Early
responsiveness of women with osteoporosis to teriparatide after
therapy with alendronate or risedronate. J Clin Endocrinol Metab
93:3785–3793
87. Boonen S, Marin F, Obermayer-Pietsch B, Simões ME, Barker C,
Glass EV, Hadji P, Lyritis G, Oertel H, Nickelsen T, McCloskey
E, EUROFORS Investigators (2008) Effects of previous
antiresorptive therapy on the bone mineral density response to
two years of teriparatide treatment in postmenopausal women with
osteoporosis. J Clin Endocrinol Metab 93:852–860

88.

Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM,
Burnett-Bowie SA (2015) Denosumab and teriparatide transitions
in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet 386:1147–1155
89. Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E,
Ferrari S, Hofbauer LC, Lau E, Lewiecki EM, Miyauchi A,
Zerbini CAF, Milmont CE, Chen L, Maddox J, Meisner PD,
Libanati C, Grauer A (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375:1532–
1543
90. Hiligsmann M, Evers SM, Ben Sedrine W, Kanis JA, Ramaekers
B, Reginster JY, Silverman S, Wyers CE, Boonen A (2015) A
systematic review of cost-effectiveness analyses of drugs for postmenopausal osteoporosis. Pharmacoeconomics 33:205–224
91. Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F,
Oden A (2008) Case finding for the management of osteoporosis
with FRAX–assessment and intervention thresholds for the UK.
Osteoporos Int 19:1395–1408
92. Lippuner K, Johansson H, Borgström F, Kanis JA, Rizzoli R
(2012) Cost-effective intervention thresholds against osteoporotic
fractures based on FRAX® in Switzerland. Osteoporos Int 23:
2579–2589
93. McCloskey E, Kanis JA, Johansson H, Harvey N, Odén A,
Cooper A, Cooper C, Francis RM, Reid DM, Marsh D, Selby P,
Thompson F, Hewitt S, Compston J (2015) FRAX-based assessment and intervention thresholds – an exploration of thresholds in
women aged 50 years and older in the UK. Osteoporos Int 26:
2091–2099
94. Hiligsmann M, Williams SA, Fitzpatrick LA, Silverman SS,
Weiss R, Reginster JY (2020) Cost-effectiveness of sequential
treatment with abaloparatide followed by alendronate vs.
alendronate monotherapy in women at increased risk of fracture:
a US payer perspective. Semin Arthritis Rheum 50:394–400
95. Chandran M, Ganesan G, Tan KB, Reginster JY, Hiligsmann M
(2021) Cost-effectiveness of FRAX®-based intervention thresholds for management of osteoporosis in Singaporean women.
Osteoporos Int 32:133–144. https://doi.org/10.1007/s0019800020-05536-00194
96. Cui L, He T, Jiang Y, Li M, Wang O, Jiajue R, Chi Y, Xu Q, Xing
X, Xia W (2020) Predicting the intervention threshold for initiating osteoporosis treatment among postmenopausal women in
China: a cost-effectiveness analysis based on real-world data.
Osteoporos Int 31:307–316
97. Li N, Zheng B, Liu M, Zhou H, Zhao L, Cai H, Huang J (2019)
Cost-effectiveness of antiosteoporosis strategies for postmenopausal women with osteoporosis in China. Menopause 26:906–
914
98. Yoshizawa T, Nishino T, Okubo I, Yamazaki M (2018) Costeffectiveness analysis of drugs for osteoporosis treatment in elderly Japanese women at high risk of fragility fractures: comparison
of denosumab and weekly alendronate. Arch Osteoporos 13:94
99. Moriwaki K, Mouri M, Hagino H (2017) Cost-effectiveness analysis of once-yearly injection of zoledronic acid for the treatment of
osteoporosis in Japan. Osteoporos Int 28:1939–1950
100. Karnon J, Shafie AS, Orji N, Usman SK (2016) What are we
paying for? A cost-effectiveness analysis of patented denosumab
and generic alendronate for postmenopausal osteoporotic women
in Australia. Cost Eff Resour Alloc 14:11
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Osteoporos Int

Affiliations
M. Chandran 1 & P. J. Mitchell 2 & T. Amphansap 3 & S. K. Bhadada 4 & M. Chadha 5 & D.-C. Chan 6 & Y.-S. Chung 7 &
P. Ebeling 8 & N. Gilchrist 9 & A. Habib Khan 10 & P. Halbout 11 & F. L. Hew 12 & H.-P. T. Lan 13 & T. C. Lau 14 & J. K. Lee 15 &
S. Lekamwasam 16 & G. Lyubomirsky 17 & L. B. Mercado-Asis 18 & A. Mithal 19 & T. V. Nguyen 20 & D. Pandey 21 & I. R. Reid 22 &
A. Suzuki 23 & T. T. Chit 24 & K. L. Tiu 25 & T. Valleenukul 26 & C. K. Yung 27 & Y. L. Zhao 28 & on behalf of the Asia Pacific
Consortium on Osteoporosis (APCO)
1

15

Department of Orthopedics, Beacon International Specialist Centre,
Petaling Jaya, Malaysia

16

Faculty of Medicine, University of Ruhuna, Galle, Sri Lanka

17

Osteoporosis Australia, Sydney, Australia

18

Faculty of Medicine and Surgery, University of Santo Tomas,
Manila, Philippines

19

Endocrinology, Diabetes Division, Mithal, M. Max Healthcare Pan-Max, Gurgaon, India

20

Internal Medicine, National University Hospital Chu-Tung Branch,
Chinese Taipei, Taiwan

Genetics and Epidemiology of Osteoporosis Laboratory, Bone
Biology Division, Garvan Institute of Medical Reseach,
Sydney, Australia

21

Department of Endocrinology and Metabolism, Ajou University
School of Medicine, Suwon, South Korea

Department of Orthopaedics, National Trauma Centre,
Kathmandu, Nepal

22

Department of Medicine in the School of Clinical Sciences, Monash
Health, Melbourne, Australia

Faculty of Medical and Health Sciences, University of Auckland,
Auckland, New Zealand

23

Department of Endocrinology, School of Medicine, Fujita Health
University, Toyoake, Japan

24

East Yangon General Hospital, Yangon, Myanmar

25

Polytrauma and Fragility Fracture team, Department of
Orthopaedics and Traumatology, Queen Elizabeth Hospital, Hong
Kong, SAR, China

26

Department of Orthopedics, Bhumibol Adulyadej Hospital,
Bangkok, Thailand

27

Department of Endocrinology and Patient Safety Unit, Raja Isteri
Pengiran Anak Saleha Hospital, Bandar Seri Begawan, Brunei
Darussalam

28

Department of Obstetrics and Gynecology, Beijing United Family
Hospital, Beijing, China

Department of Endocrinology, Osteoporosis and Bone Metabolism
Unit, Singapore General Hospital, 20, College Road, Academia,
Singapore 169856, Singapore

2

Synthesis Medical NZ Limited, Pukekohe, Auckland, New Zealand

3

Department of Orthopedics, Police General Hospital,
Bangkok, Thailand

4

5

6

7

8

9
10

Department of Endocrinology, Postgraduate Institute of Medical
Education and Research, Chandigarh, India
Department of Endocrinology, Hinduja Hospital and Research
Centre, Mumbai, India

Canterbury District Health Board, Christchurch, New Zealand
Section of Chemical Pathology, Department of Pathology and
Laboratory Medicine, Aga Khan University, Karachi, Pakistan

11

International Osteoporosis Foundation, Nyon, Switzerland

12

Department of Medicine, Subang Jaya Medical Centre, Subang
Jaya, Malaysia

13

14

Musculoskeletal and Metabolic Unit, Biomedical Research Center,
Pham Ngoc Thach University of Medicine, Bone and Muscle
Research Group, Ton Duc Thang University, Ho Chi Minh
City, Vietnam
Division of Rheumatology, Department of Medicine, National
University Hospital, Singapore, Singapore

